Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

3,970 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma.
Luginbuhl AJ, Johnson JM, Harshyne LA, Linnenbach AJ, Shukla SK, Alnemri A, Kumar G, Cognetti DM, Curry JM, Kotlov N, Antysheva Z, Degryse S, Mannion K, Gibson MK, Netterville J, Brown B, Axelrod R, Zinner R, Tuluc M, Gargano S, Leiby BE, Shimada A, Mahoney MG, Martinez-Outschoorn U, Rodeck U, Kim YJ, South AP, Argiris A. Luginbuhl AJ, et al. Among authors: kumar g. Clin Cancer Res. 2022 Mar 1;28(5):915-927. doi: 10.1158/1078-0432.CCR-21-1816. Clin Cancer Res. 2022. PMID: 34911681 Free PMC article. Clinical Trial.
Inhibition of LSD1 Attenuates Oral Cancer Development and Promotes Therapeutic Efficacy of Immune Checkpoint Blockade and YAP/TAZ Inhibition.
Alhousami T, Diny M, Ali F, Shin J, Kumar G, Kumar V, Campbell JD, Noonan V, Hanna GJ, Denis GV, Monti S, Kukuruzinska MA, Varelas X, Bais MV. Alhousami T, et al. Among authors: kumar g, kumar v. Mol Cancer Res. 2022 May 4;20(5):712-721. doi: 10.1158/1541-7786.MCR-21-0310. Mol Cancer Res. 2022. PMID: 35105672 Free PMC article.
IL-8 correlates with nonresponse to neoadjuvant nivolumab in HPV positive HNSCC via a potential extracellular vesicle miR-146a mediated mechanism.
Hill BL, Calder AN, Flemming JP, Guo Y, Gilmore SL, Trofa MA, Daniels SK, Nielsen TN, Gleason LK, Antysheva Z, Demina K, Kotlov N, Davitt CJH, Cognetti DM, Prendergast GC, Snook AE, Johnson JM, Kumar G, Linnenbach AJ, Martinez-Outschoorn U, South AP, Curry JM, Harshyne LA, Luginbuhl AJ, Mahoney MG. Hill BL, et al. Among authors: kumar g. Mol Carcinog. 2023 Sep;62(9):1428-1443. doi: 10.1002/mc.23587. Epub 2023 Jul 4. Mol Carcinog. 2023. PMID: 37401875
Targeting Chemotherapy to Decondensed H3K27me3-Marked Chromatin of AML Cells Enhances Leukemia Suppression.
Porazzi P, Petruk S, Pagliaroli L, De Dominici M, Deming D 2nd, Puccetti MV, Kushinsky S, Kumar G, Minieri V, Barbieri E, Deliard S, Grande A, Trizzino M, Gardini A, Canaani E, Palmisiano N, Porcu P, Ertel A, Fortina P, Eischen CM, Mazo A, Calabretta B. Porazzi P, et al. Among authors: kumar g. Cancer Res. 2022 Feb 1;82(3):458-471. doi: 10.1158/0008-5472.CAN-21-1297. Epub 2021 Dec 13. Cancer Res. 2022. PMID: 34903608 Free PMC article.
Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma.
Capparelli C, Purwin TJ, Glasheen M, Caksa S, Tiago M, Wilski N, Pomante D, Rosenbaum S, Nguyen MQ, Cai W, Franco-Barraza J, Zheng R, Kumar G, Chervoneva I, Shimada A, Rebecca VW, Snook AE, Hookim K, Xu X, Cukierman E, Herlyn M, Aplin AE. Capparelli C, et al. Among authors: kumar g. Nat Commun. 2022 Mar 16;13(1):1381. doi: 10.1038/s41467-022-28801-y. Nat Commun. 2022. PMID: 35296667 Free PMC article.
Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs.
De Dominici M, Porazzi P, Xiao Y, Chao A, Tang HY, Kumar G, Fortina P, Spinelli O, Rambaldi A, Peterson LF, Petruk S, Barletta C, Mazo A, Cingolani G, Salvino JM, Calabretta B. De Dominici M, et al. Among authors: kumar g. Blood. 2020 Apr 30;135(18):1560-1573. doi: 10.1182/blood.2019003604. Blood. 2020. PMID: 32040545 Free PMC article.
3,970 results